Drug Profile
R 548
Alternative Names: R-548Latest Information Update: 12 Sep 2015
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 12 Sep 2015 Discontinued - Phase-I for Transplant rejection (In volunteers) in USA (PO)
- 31 Dec 2011 Phase-I clinical trials in Transplant rejection in USA (PO)